

Amendment to the Specification:

Please amend page 1, lines 4-6 of the application as follows.

This application is a continuation-in-part of U.S. Serial No. 09/724,842, filed November 28, 2000 (pending), and claims the benefit of priority under 35 U.S.C. 119(e) to ~~co~~pending U.S. Provisional Application No. 60/168,594, filed on November 29, 1999 (now abandoned), the entire contents of each of which are incorporated herein by reference.

Please amend page 17, lines 16-21 and page 18, line 9 of the application as follows.

FIG. 1 illustrates the targeted sites for the antigenic fragments (SEQ ID NO:1).

FIG. 2 illustrates the effect of 1 mg/ml of antibodies raised against D and L forms of A β (16-21) (SEQ ID NO:7) on fibrillogenesis.

FIG. 3 illustrates the effect of 0.5 mg/ml of antibodies raised against D and L forms of A β (16-21) (SEQ ID NO:7) on fibrillogenesis.

FIG. 7 illustrates the response of rabbits to KLH-conjugated all-L and all-D KLVFFA (SEQ ID NO:7).